Consumer perception, knowledge, and uses of cannabidiol

Cambrey Nguyen, Karen E. Moeller, Michael McGuire, Brittany L. Melton
{"title":"Consumer perception, knowledge, and uses of cannabidiol","authors":"Cambrey Nguyen, Karen E. Moeller, Michael McGuire, Brittany L. Melton","doi":"10.9740/mhc.2023.10.217","DOIUrl":null,"url":null,"abstract":"Abstract Introduction The legalization of cannabidiol (CBD) across the United States, in varying degrees, has made CBD easily accessible to consumers for complementary and medical purposes. However, there is a paucity of scientific evidence on the benefits and risks of commercially available CBD. In the literature, 2 studies have gathered consumer perceptions and attitudes on cannabis products, specifically CBD, using survey-based questionnaires. This study aimed to build on the aforementioned studies in obtaining consumer perception and knowledge of CBD products using a national survey-based questionnaire. Methods Respondents were recruited through an anonymous, nationwide, online survey administered through Qualtrics in the United States from March 28 to April 30, 2021. The survey consisted of demographics, perceived efficacy and safety of CBD, and resources to obtain CBD information. The survey responses were reported using descriptive statistics along with median and interquartile range for the Likert portion. Results A total of 1158 respondents accessed the survey. The median age was 43 and 50% of respondents were female. The uses for CBD included neurological disorders, pulmonary conditions, gastrointestinal disorders, and chronic pain. The most commonly reported safety concern related to taking CBD was anxiety. Participants agreed that CBD is safe when used responsibly for medical use, and social media was the main source used to obtain information about CBD. Discussion Respondents who used CBD for a condition thought it was helpful; however, most of the adverse effects were rated as moderate to severe, requiring medical attention from a health care professional, hospital, or emergency room visit.","PeriodicalId":22710,"journal":{"name":"The Mental Health Clinician","volume":"23 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Mental Health Clinician","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.9740/mhc.2023.10.217","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Abstract Introduction The legalization of cannabidiol (CBD) across the United States, in varying degrees, has made CBD easily accessible to consumers for complementary and medical purposes. However, there is a paucity of scientific evidence on the benefits and risks of commercially available CBD. In the literature, 2 studies have gathered consumer perceptions and attitudes on cannabis products, specifically CBD, using survey-based questionnaires. This study aimed to build on the aforementioned studies in obtaining consumer perception and knowledge of CBD products using a national survey-based questionnaire. Methods Respondents were recruited through an anonymous, nationwide, online survey administered through Qualtrics in the United States from March 28 to April 30, 2021. The survey consisted of demographics, perceived efficacy and safety of CBD, and resources to obtain CBD information. The survey responses were reported using descriptive statistics along with median and interquartile range for the Likert portion. Results A total of 1158 respondents accessed the survey. The median age was 43 and 50% of respondents were female. The uses for CBD included neurological disorders, pulmonary conditions, gastrointestinal disorders, and chronic pain. The most commonly reported safety concern related to taking CBD was anxiety. Participants agreed that CBD is safe when used responsibly for medical use, and social media was the main source used to obtain information about CBD. Discussion Respondents who used CBD for a condition thought it was helpful; however, most of the adverse effects were rated as moderate to severe, requiring medical attention from a health care professional, hospital, or emergency room visit.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
消费者对大麻二酚的认知、知识和使用
大麻二酚(CBD)在美国各地的合法化,在不同程度上使得消费者很容易获得CBD作为补充和医疗目的。然而,关于商用CBD的益处和风险的科学证据缺乏。在文献中,有两项研究使用基于调查的问卷收集了消费者对大麻产品,特别是CBD的看法和态度。本研究的目的是在上述研究的基础上,利用全国性的调查问卷来获得消费者对CBD产品的认知和知识。研究人员于2021年3月28日至4月30日在美国通过Qualtrics进行匿名全国在线调查。调查内容包括人口统计学、CBD的有效性和安全性以及获取CBD信息的资源。调查结果使用描述性统计以及李克特部分的中位数和四分位数范围进行报告。结果共有1158名被调查者参与了调查。中位年龄为43岁,50%的受访者是女性。CBD的用途包括神经系统疾病、肺部疾病、胃肠道疾病和慢性疼痛。与服用CBD有关的最常见的安全问题是焦虑。与会者一致认为,当负责任地用于医疗用途时,CBD是安全的,社交媒体是获取CBD信息的主要来源。使用CBD治疗某种疾病的受访者认为它是有帮助的;然而,大多数不良反应被评为中度至重度,需要医疗保健专业人员,医院或急诊室就诊。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Exploring real-world symptom impact and improvement in well-being domains for tardive dyskinesia in VMAT2 inhibitor-treated patients via clinician survey and chart review Impact of Board Certified Psychiatric Pharmacists on improving urinary tract infection antibiotic appropriateness at an acute psychiatric hospital Barriers to access to psychiatric medications in Missouri county jails Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports Intranasal ketamine as a treatment for psychiatric complications of long COVID: A case report
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1